Close Menu


Cancer centers are investing in testing and decision support tools to personalize cancer care, though the COVID-19 pandemic has presented challenges.

Researchers surveyed 171 physicians in the NCI-MATCH study to determine their tumor profiling practices and barriers to participation in future studies.

An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.

The survey results point to the need for greater education among patients so they can better advocate for themselves.